Global COVID-19 Traditional Chinese Medicine Treatment Market Research Report 2022

Traditional Chinese medicine has been playing a critical role in the prevention, treatment and rehabilitation of the COVID-19.Official figures showed that, up to Sunday, 91.6 percent of the patients in Hubei province, the epicenter of the outbreak, and 92.4 percent of the patients nationwide have been treated with TCM."Three formulas and three medicines" have been proven to be effective in curbing the virus, according to the State Administration of Traditional Chinese Medicine.
Due to the COVID-19 pandemic, the global COVID-19 Traditional Chinese Medicine Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe COVID-19 Traditional Chinese Medicine Treatment market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe COVID-19 Traditional Chinese Medicine Treatment landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Lianhua Qingwen Capsule accounting for % of the COVID-19 Traditional Chinese Medicine Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of COVID-19 Traditional Chinese Medicine Treatment include Shijiazhuang Yiling Pharmaceutical, Tianjin Chase Sun Pharmaceutical, Beijing Juxiechang Pharmaceutical and Beijing Yiling Pharmaceutical, etc. In terms of revenue, the global 3 largest players have a % market share of COVID-19 Traditional Chinese Medicine Treatment in 2021.
This report focuses on COVID-19 Traditional Chinese Medicine Treatment volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall COVID-19 Traditional Chinese Medicine Treatment market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global COVID-19 Traditional Chinese Medicine Treatment Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Lianhua Qingwen Capsule
Xuebijing Injection
Jinhua Qinggan Granule
Segment by Application
Hospital
Special Clinic
Recovery Center
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Shijiazhuang Yiling Pharmaceutical
Tianjin Chase Sun Pharmaceutical
Beijing Juxiechang Pharmaceutical
Beijing Yiling Pharmaceutical